This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Jumonji domain containing 1A (JMJD1A; TSGA)	<p>Mouse and cell culture studies suggest inhibiting JMJD1A could help circumvent resistance to antiangiogenic cancer therapies. In four human cancer cell lines, hypoxic and nutrient-starved conditions led to greater expression of JMJD1A than nonstressed conditions. In two mouse xenograft models for human cancers, small interfering RNA against JMJD1A increased tumor sensitivity to the antiangiogenic drugs Avastin bevacizumab and Sutent sunitinib compared with scrambled siRNA. Next steps could include screening for pharmacological inhibitors of JMJD1A.</p> <p>Roche's Genentech Inc. unit markets Avastin, a humanized mAb against VEGF, to treat colorectal, lung, renal and brain cancers. Pfizer Inc. markets Sutent, a small molecule that inhibits multiple receptor tyrosine kinases including VEGF receptors, to treat GI, pancreatic and renal cancers.</p> <p>SciBX 6(13); doi:10.1038/scibx.2013.309 Published online April 4, 2013</p>	Patent and licensing status unavailable	<p>Osawa, T. <i>et al. Cancer Res.</i>; published online March 14, 2013; doi:10.1158/0008-5472.CAN-12-3231</p> <p>Contact: Masabumi Shibuya, Tokyo Medical and Dental University, Tokyo, Japan e-mail: shibuya@ims.u-tokyo.ac.jp</p>